RadioMedix and Curium Announce copper Cu 64 dotatate injection was granted priority review by the U.S. FDA

RadioMedix

11 March 2020 - RadioMedix and its commercial partner Curium announced the U.S. FDA has granted copper Cu 64 dotatate injection a priority review. 

Copper Cu 64 dotatate is a PET diagnostic agent intended for somatostatin receptor expressing neuroendocrine tumours. 

Curium is preparing to launch copper Cu 64 dotatate in Q3 of this year.

Read RadioMedix press release

Michael Wonder

Posted by:

Michael Wonder